Daily Endocrinology Research Analysis
Analyzed 85 papers and selected 3 impactful papers.
Summary
Three impactful studies advance endocrine science and care: (1) a mechanistic study identifies a BAF60C–REG3B axis linking nucleolar stress to β-cell failure in type 2 diabetes; (2) translational work implicates GDF15 as a mediator of symptoms and counterregulation during hypoglycemia after bariatric surgery; and (3) a diagnostic accuracy study shows near-perfect performance of CYFRA 21-1 in lymph node washouts for detecting metastatic differentiated thyroid cancer.
Research Themes
- Islet stress-immune crosstalk driving β-cell dysfunction in type 2 diabetes
- Hormonal mediators and biomarkers of post-bariatric hypoglycemia
- Precision diagnostics in thyroid oncology using washout biomarkers
Selected Articles
1. BAF60C links nucleolar stress to β cell dysfunction in type 2 diabetes through controlling Reg3b mRNA decay.
This mechanistic study identifies BAF60C as a chromatin factor that restrains nucleolar stress and maintains β-cell function by stabilizing Reg3b mRNA, thereby dampening islet inflammation via REG3B-mediated β cell–macrophage crosstalk. β cell-specific loss of BAF60C worsened hyperglycemia and inflammation, while REG3B supplementation or exercise rescued metabolic and inflammatory phenotypes.
Impact: It uncovers a previously unrecognized β-cell intrinsic pathway—BAF60C–REG3B—that links nucleolar stress to islet inflammation and dysfunction, offering testable therapeutic levers (REG3B, exercise, nucleolar stress modulation).
Clinical Implications: Although preclinical, the BAF60C–REG3B axis suggests new targets to preserve β-cell function in T2D and supports exercise as a modulator of islet stress/inflammation.
Key Findings
- β cell dysfunction in T2D associates with elevated nucleolar stress and reduced BAF60C expression in human and mouse islets.
- β cell-specific BAF60C deletion exacerbates HFD-induced hyperglycemia, nucleolar stress, and islet inflammation; overexpression is protective.
- BAF60C forms a complex with NPM1 and Reg3b mRNA to control Reg3b mRNA decay, promoting REG3B secretion that modulates β cell–macrophage crosstalk.
- Restoration of the BAF60C–REG3B axis via REG3B supplementation or exercise alleviates islet inflammation and improves glucose homeostasis.
Methodological Strengths
- Multi-system validation including human T2D islets, β cell-specific genetic mouse models, and interventional rescue (REG3B, exercise).
- Mechanistic dissection of RNA–protein complex (BAF60C–NPM1–Reg3b mRNA) linking chromatin remodeling to mRNA decay.
Limitations
- Human causal inference remains indirect; primary human interventional data are lacking.
- Translatability of REG3B-based therapies requires safety and efficacy testing in humans.
Future Directions: Develop small molecules or biologics to enhance BAF60C function or REG3B signaling; test nucleolar stress modulators and exercise-mimetic strategies in early T2D.
The islet immune microenvironment contributes critically to β cell dysfunction in type 2 diabetes (T2D), but its regulatory mechanisms remain unclear. We show that β cell dysfunction in T2D patients and diabetic mice correlates with elevated nucleolar stress and reduced expression of BAF60C, a switching defective/sucrose nonfermenting (SWI/SNF) chromatin-remodeling factor. β cell-specific BAF60C deletion aggravates high-fat diet (HFD)-induced hyperglycemia, nucleolar stress, and islet inflammation, whereas BAF60C overexpression displays protection. BAF60C suppresses islet inflammation by promoting REG3B expression and secretion, thereby modulating β cell-macrophage crosstalk. Mechanistically, BAF60C forms an RNA-protein complex with nucleophosmin (NPM1) and Reg3b mRNA to modulate Reg3b mRNA decay. Restoration of the BAF60C-REG3B axis through REG3B supplementation or exercise alleviates inflammation and improves glucose homeostasis in obese and T2D mice, revealing a non-canonical role for BAF60C in linking nucleolar stress to β cell failure.
2. Plasma GDF15 increases during hyperinsulinemic hypoglycemia in humans with post-bariatric hypoglycemia and after insulin exposure in mice.
Plasma GDF15 is elevated at baseline and during insulin-induced hypoglycemia in individuals with post-bariatric hypoglycemia, correlating with symptom burden. In mice, insulin-induced hypoglycemia increases GDF15, and exogenous GDF15 reduces hypoglycemia-driven feeding, suggesting a role for GDF15 in modulating counterregulation and symptoms.
Impact: Identifies GDF15 as a candidate biomarker and mediator of hypoglycemia-related symptoms in PBH with convergent human clamp and mouse data, opening avenues for targeted symptom management.
Clinical Implications: GDF15 measurement may aid phenotyping and monitoring in PBH; modulation of GDF15 signaling could be explored to alleviate symptom burden during hypoglycemia.
Key Findings
- Fasting and postprandial plasma GDF15 levels are higher in PBH compared to overweight/obese controls without surgery.
- During hyperinsulinemic hypoglycemic clamp, GDF15 rises progressively in PBH and correlates with symptom scores (e.g., weakness, cognitive difficulty).
- Insulin-induced hypoglycemia elevates GDF15 in mice, and recombinant GDF15 reduces hypoglycemia-driven food intake.
Methodological Strengths
- Translational approach combining human phenotyping, hyperinsulinemic hypoglycemic clamps, and mouse experiments.
- Symptom-correlated biomarker analysis providing mechanistic linkage between endocrine signal and clinical phenotype.
Limitations
- Sample sizes and demographic diversity are not detailed; external validation in larger PBH cohorts is needed.
- Causality in humans remains inferential; interventional modulation of GDF15 was not tested clinically.
Future Directions: Validate GDF15 as a biomarker in multicenter PBH cohorts; test GDF15 pathway modulators for symptom control; define thresholds linking GDF15 dynamics to hypoglycemia severity.
Post-bariatric hypoglycemia (PBH), characterized by excessive postprandial incretin and insulin secretion, is a common complication of bariatric surgery. Here, we investigate the relationship between PBH and growth differentiation factor 15 (GDF15) in individuals with PBH after Roux-en-Y gastric bypass (RYGB), post-RYGB individuals who remain asymptomatic (Asx), and individuals with overweight/obesity but without history of surgery (Ow/Ob). Fasting plasma GDF15 is higher in PBH vs. Ow/Ob and further increases postprandially, coinciding with hypoglycemia symptoms. During a hyperinsulinemic hypoglycemic clamp, GDF15 progressively increases in PBH and correlates with hypoglycemia survey symptoms, including weakness, difficulty concentrating, feeling cold, and tingling lips. In mice, insulin-induced hypoglycemia also results in elevated GDF15 levels, and exogenous recombinant GDF15 (rGDF15) reduces food intake in response to hypoglycemia. Our data suggest that GDF15 modulates the counterregulatory response to hypoglycemia in both PBH individuals and mice and that elevated GDF15 levels contribute to hypoglycemia-related postprandial symptoms. This study was registered at ClinicalTrials.gov (NCT04428866).
3. CYFRA 21-1 in lymph node fine-needle aspiration washouts: added value in differentiated thyroid cancer.
In 226 suspicious cervical nodes from DTC patients, FNA washout CYFRA 21-1 achieved near-perfect discrimination (AUC 0.99) for metastasis, comparable to FNAC plus FNA-Tg and robust to anti-Tg antibody status. Adding washout biomarkers markedly improved diagnostic accuracy over cytology alone.
Impact: Provides a practical, high-accuracy biomarker to improve preoperative nodal staging in DTC, especially when cytology is indeterminate or Tg measurement is confounded.
Clinical Implications: Incorporating FNA-CYFRA 21-1 into multimodal assessment can enhance diagnostic confidence and guide surgical planning, particularly in anti-Tg antibody–positive patients or Tg-challenging cases.
Key Findings
- FNA-CYFRA 21-1 demonstrated near-perfect discrimination for metastatic vs. benign nodes (AUC 0.99; 95% CI 0.99–1.00).
- Adding FNA-Tg to FNAC significantly improved diagnostic performance (AUC 0.98 vs. 0.91; p=0.0003).
- Diagnostic accuracy of FNA-CYFRA 21-1 remained robust regardless of anti-thyroglobulin antibody status.
Methodological Strengths
- Head-to-head comparison of FNAC, FNA-Tg, and FNA-CYFRA 21-1 with histopathology/composite follow-up as reference standard.
- Robust ROC analysis, multivariable modeling, and DeLong testing; performance evaluated across anti-Tg antibody strata.
Limitations
- Single observational cohort without external validation; generalizability to other centers/laboratories requires confirmation.
- Thresholds and assay standardization for FNA-CYFRA 21-1 across platforms remain to be harmonized.
Future Directions: Prospective multicenter validation with standardized assay protocols and clinical utility studies to assess impact on surgical decision-making and outcomes.
OBJECTIVES: Cervical lymph node metastases represent a key challenge in patients with differentiated thyroid carcinoma (DTC). Fine-needle aspiration cytology (FNAC) and thyroglobulin (Tg) measurement in fine-needle washout (FNA-Tg) are widely used but have recognized limitations. Cytokeratin 19 fragment 21-1 measurement in FNA washout (FNA-CYFRA 21-1) has recently emerged as a potential supplementary biomarker. We compared the diagnostic performance of FNAC, FNA-Tg and FNA-CYFRA 21-1 in a series of well characterized DTC patients. METHODS: In this observational diagnostic accuracy study, 226 suspicious cervical lymph nodes were assessed by FNAC, FNA-Tg and FNA-CYFRA 21-1. The reference standard was histopathology or a predefined composite clinical follow-up. Receiver operating characteristic (ROC) analysis, logistic regression, and DeLong's test were applied. RESULTS: Of 226 lymph nodes, 87 were metastatic and 139 benign. FNA-CYFRA 21-1 showed near-perfect discrimination (AUC 0.99, 95 % CI 0.99-1.00), followed by FNA-Tg (AUC 0.97, 95 % CI 0.94-0.98). FNAC demonstrated high specificity but lower sensitivity (positivity: 79.3 % in metastatic vs. 3.6 % in benign nodes). In multivariable models, adding washout Tg significantly improved discrimination over FNAC alone (AUC 0.98 vs. 0.91; p=0.0003). A model based solely on FNA-CYFRA 21-1 achieved the highest performance (AUC 0.99), comparable to FNAC combined with FNA-Tg (p=0.09). Diagnostic accuracy remained robust across anti-thyroglobulin antibody strata. CONCLUSIONS: FNA-CYFRA 21-1 provides excellent diagnostic accuracy for metastatic cervical lymph nodes in DTC and performs at least comparably to established approaches. Its integration into a multimodal strategy may enhance diagnostic confidence, particularly in cytologically indeterminate or Tg-challenging scenarios.